Zafgen studies ZGN-1061 in Phase II trial for type 2 diabetes

US-based biopharmaceutical firm Zafgen has started a Phase II clinical trial of its second-generation MetAP2 inhibitor ZGN-1061 to treat patients with type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news